Health Care • Biotechnology: Pharmaceutical Preparations
$70.32 ▼ -1.59
(-2.21%)
MKT CAP: $472.0M • VOL: 197.8K
52W L $50 52W H $125
ROARABLE / RQD
E • 27/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$59
MEDIAN
$79
MEAN
$80
HIGH
$96
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MNPR TAPE
MNPR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $85.09 | $80.87 | 2025-02-14 | $63.99 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $88.60 | $82.98 | 2025-02-06 | $66.10 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $80.16 | $77.35 | 2025-01-29 | $67.51 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $71.73 | — | 2025-01-17 | $68.91 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $61.88 | $66.80 | 2025-01-09 | $62.58 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $83.68 | $73.13 | 2024-12-18 | $61.18 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $68.21 | $71.02 | 2024-12-04 | $65.40 | -4.3% | 48% | C |